戻る Agenda
Session 3: An In-Depth Look at EPAD
Session Chair(s)
Scott Berry, PHD
President and Senior Statistical Scientist
Berry Consultants LLC, United States
Daniel Millar, MBA
Senior Director, Strategic Business Transformation
Johnson & Johnson, United States
The I-Spy2 trial helped create the platform trial. It has had an amazing record of success and innovation. EPAD is an IMI sponsored phase II platform trial in Alzheimer’s disease and has the potential to change the course of Alzheimer’s with the innovative platform trial. Each of these trials will be presented and discussed in-depth both from a design, operation, and strategy perspective.
Speaker(s)
Lisa Ford
Janssen Pharmaceuticals, United States
Senior Director, Neuroscience Research and Development
An In-Depth Look at EPAD
Mark Fitzgerald, PHD
Berry Consultants LLC, United States
Statistical Scientist